Enlivex Therapeutics Ltd
Healthcare · EUR · F
Price
€0.61
Cap
€185.61M
Earnings
—
30d Trend
-20.7%
78% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 32×Macro 0.99 (−1%)=32
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 60%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Enlivex Therapeutics Ltd at 32/100 — a WEAK reading on the Brain47 Signal. The strongest factor is quality at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-5.3%
3 MONTHS
-32.0%
12 MONTHS
-17.7%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Quality (50) and Fundamentals (50) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 78%. I classify this as a speculative position — elevated volatility at 78% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.